FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and

Manish Kumar1, Abhishek Singh Sengar2, Anushree Lye3

  • 1Centre of Biomedical Research, Raebareli Road, Lucknow, Uttar Pradesh, 226014, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.

Redox Biology
|February 9, 2025
PubMed

Insights

Fibronectin type III domain-containing protein 5 (FNDC5) depletion exacerbates doxorubicin cardiotoxicity by activating ATR/Chk1. Restoring FNDC5 protects the heart from chemotherapy-induced damage, highlighting its therapeutic potential.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Oncology Therapeutics

Background:

  • Anthracycline chemotherapy, like doxorubicin, causes cardiotoxicity, limiting its clinical use.
  • Doxorubicin-induced heart damage is linked to DNA damage and oxidative stress.
  • The role of specific proteins in mitigating this cardiotoxicity remains incompletely understood.

Purpose of the Study:

  • To investigate the role of fibronectin type III domain-containing protein 5 (FNDC5) in doxorubicin-induced cardiotoxicity.
  • To elucidate the molecular mechanisms by which FNDC5 influences cardiomyocyte survival and cardiac function.
  • To explore the therapeutic potential of FNDC5/irisin in preventing chemotherapy-associated cardiomyopathy.

Main Methods:

  • Assessed FNDC5 expression in human and murine hearts exposed to chemotherapeutics.
  • Utilized cardiomyocytes and murine models to study FNDC5 restoration and depletion effects.
  • Analyzed reactive oxygen species (ROS) accumulation, apoptosis, signaling pathways (ATR/Chk1), and cardiac function.

Main Results:

  • FNDC5 is depleted in hearts affected by chemotherapeutics.
  • Restoring FNDC5 in cardiomyocytes mitigates doxorubicin-induced ROS and apoptosis via irisin signaling.
  • FNDC5 depletion activates the ATR/Chk1 pathway, leading to cardiac dysfunction, fibrosis, and reduced survival, which can be reversed by Chk1 inhibition.

Conclusions:

  • FNDC5/irisin plays a crucial protective role against doxorubicin cardiotoxicity by modulating ROS and the ATR/Chk1 pathway.
  • Targeting FNDC5/irisin or Chk1 presents a potential therapeutic strategy for chemotherapy-induced cardiotoxicity.
  • Age-related FNDC5 downregulation may impair cardioprotection, emphasizing FNDC5's importance in cardiac health throughout life.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
10.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K